Check-Cap to merge with MBody AI in embodied AI workforce push
LONDON - Trellus Health plc (AIM:TRLS) issued a correction to its interim financial results on Monday, amending its previously reported adjusted EBITDA loss figure for the six months ended June 30, 2025.
The healthcare company, which delivers digital platforms for managing complex chronic conditions, stated that the adjusted EBITDA loss was incorrectly reported as $3.5 million in its earlier announcement. The correct figure is a loss of $2.6 million, which the company noted is in line with management expectations.
No other changes were made to the interim results, which showed revenue of $379,000 for the first half of 2025, compared to $50,000 in the same period last year. The company reported net cash of $1.6 million as of June 30, 2025, down from $4.3 million at the end of December 2024.
Trellus Health’s cash runway extends into early November 2025, according to the company. The board intends to explore a possible fundraising in the coming weeks, with the structure and amount to be determined.
The company highlighted several operational achievements, including a milestone agreement with Johnson & Johnson Health Care Systems Inc signed in January, preferred vendor status granted by a leading global Contract Research Organisation in June, and renewal of a Pfizer licensing agreement for IBD digital patient support content in May.
Trellus has further reduced its average monthly cash burn by approximately 10% to $440,000 per month since August 1, 2025.
The company’s Trellus Elevate platform integrates data analytics with personalized resilience programs for managing chronic conditions across pharmaceutical patient support programs, clinical trial services, and the U.S. health plan sector, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.